natgillin/translations-raw huggingface dataset:
This salt is prepared by adding one molar equivalent of an ethanolic solution of maleic acid to an ethanolic solution of asenapine 1, according to example 1. 
Ova sol se dobiva dodatkom jednog molarnog ekvivalenta etanolske otopine maleinska kiseline u etanolsku otopinu asenapina 1, prema primjeru 1.
Protocol for Study C: Cytogenetics Study in Chinese Hamster Ovary Cells 
Protokol za studiju C: citogenetička studija u stanicama jajnika kineskog hrčka
In some embodiments, synthetic retinal derivative is 9-cis-retinyl acetate or 11-cis-retinyl acetate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 4, naznačen time, da je 9-cis-retinil ester 9-cis-retinil acetat.
During the negative half-wave, instead, the path for the bias current of triac 88 comprises diode 102, resistor 103 and transistor 105; in both cases a current flows through resistor 89 and the triac 88 is on. 
Za vrijeme negativne poluperiode, struja napajanja trijaka 88 prolazi kroz diodu 102, otpornik 103 i tranzistor 105, u oba slučaja struja teče kroz otpornik 89 i trijak 88 je uključen.
is independently selected from C1-10alkyl, haloC1-10alkyl, C3-10cycloalkyl, C6-10aryl, a 4- to 12-membered heteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, S, or O; 
je nezavisno odabrano od C1-10alkil, haloC1-10alkil, C3-10cikloalkil, C6-10aril, 4- do 12-člani heteroaril ili 4- do 12-člani heterociklil, gdje heteroaril i heterociklil se sastoje od ugljikovih atoma i 1, 2, 3, ili 4 heteroatoma nezavisno odabranih iz grupe koja se sastoji od N, S, ili O.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A lipid compound according to claim 1, wherein the alkyl group, in the definition of R2 and R3, is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and n-hexyl. 
Lipidni spoj prema zahtjevu 1, pri čemu je alkil skupina, iz definicije za R2 i Rs, odabrana od metila, etila, n- Žž, propila, izopropila, n-butila, sec-butila i n-heksila.
Ulipristal acetate, or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in treating or preventing leiomyomatosis or metastatic leiomyoma according to anyone of claims 1 to 6, wherein it is to be administered to said patient before she undergoes surgery of the uterus. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje toj bolesnici prije nego što će ići na operaciju maternice.
k is independently an integer in the range of 1 to 10, preferably k is 1, 2, 3 or 4, most preferably k is 1; 
D je ciljna molekula; jje neovisno I, 2, 3, 41li 5; k je neovisno cijeli broj, u rasponu od 1 do 10;
More preferably, such a sequence has at least 80% identity, at least 90% identity, or most preferably at least 95% identity to the native sequence. 
11 ili sekvencu koja ima najmanje 80% identiteta sekvence sa SEQ ID No.: 6, 7, 10, ili 11.
curing the mold at 60 °C to 180°C, wherein the polysiloxane is present in a concentration of 55% to 90% by total weight of the ring. 
sušenje kalupa na temperaturi od 60 °C do 180 °C, pri čemu je polisiloksan prisutan u koncentraciji od 55 % do 90 % ukupne mase prstena.
A compound of the formula II wherein: 
Tvar formule II [image] gdje
maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin resistance; in a patient in need thereof. 
- održavanje i/ili poboljšanje osjetljivosti na inzulin i/ili liječenje ili prevencija hiperinzulinemije i/ili otpornosti na inzulin; za pacijenta kojemu je to potrebno.
Accordingly, in a first aspect of the invention, there is provided a compound of the formula I, or a pharmaceutically acceptable salt thereof: wherein: 
U skladu s tim, u prvom aspektu izuma, donosi se spoj formule [, ili farmaceutski prihvatljiva pripadna sol: gdje: Z=0iliS;
The method of claim 1, wherein the compound is administered in the form of a cream. 
Spoj za uporabu za liječenje kožne poremećaja kod pacijenta, naznačen time da se spoj primjenjuje topikalno, pri čemu
The apparatus according to Claim 1, wherein said regulation of the current delivered occurs according to a stepwise pattern. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što se navedena regulacija isporučene struje događa po stupnjevitom uzorku.
mixing compound B of the structure with toluene and ethyl acetate; heating the mixture at a temperature within the range from about 50 to about 70°C; 
B s toluenom i etil acetatom; b) zagrijavanje smjese kod temperature koja je u rasponu od oko 50 do oko 70*C; c) dodavanje 1,4-butin-diola;
The fuel gas supply system of a vessel according to claim 1, further comprising a fuel gas supply line connected from the LNG tank to the high-pressure gas injection engine of the vessel, wherein the boil-off gas reliquefaction apparatus includes a heat exchanger installed along the fuel gas supply line between the LNG tank and the high-pressure gas injection engine. 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da su sredstva za komprimiranje konfiguriranja za izvlačenje LNG iz spremnika LNG (1), stlačivanje izvučenog LNG kod visokog pritiska, te za dovođenje stlačenog LNG prema visokotlačnom plinskom injekcijskom motoru. Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da sredstva za komprimiranje sadrže jednu crpku.
The recent European Pharmacopoeia 2000 (E.P. 
Aktualna Europska farmakopeja 2000 (E.P.
A crystal of 1-(2'-cyano-2'-deoxy-B-D-arabinofuranosyl)cytosine monohydrochloride having characteristic peaks at 6.4°, 12.6°, 17.3°, and 21.7° as diffraction angles (2θ ± 0.1°) measured by powder X-ray diffraction, and having a melting point of 192°C to 197°C. 
Tip II kristala 1-(2'-cijano-2'-deoksi-B-D-arabinofuranozil)citozin monohidroklorida, naznačen time da ima karakteristične vrhove na 6.4°, 12.6°, 17.3° i 21.7° kao difrakcijske kutove (2#6 0,1°) izmjereno rendgenskom difrakcijom praha, i koji ima točku tališta od 192°C do 196°C.
In another embodiment, said incision line has a shape that is circular, oval, linear, arc of circle, square with rounded corners, rectangular with rounded corners, hexagonal with rounded corners, or a finite curved line with an irregular shape, allowing the container to be removed outside said partially detachable packaging section. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je navedena linija reza kružnog oblika, ovalnog, linearnog, kružnog luka, kvadrata sa zaobljenim kutevima ili čak zakrivljenom linijom nepravilnog oblika, koja omogućava odvajanje navedenog spremnika (2) iz navedenog djelomično odvojivog dijela ambalažnog pakiranja.
(iii)separating the solvent layers; and 
odvajanja slojeva otapala; i
The composition according to any one of the preceding claims, wherein the organic solvent is selected from the group consisting of C1-C10 alcohols, esters of C1-C10 alcohols with C1-C10 carboxylic acids, and mixtures thereof. The composition according to claim 19, wherein the organic solvent comprises a C1-C6 alcohol and an ester of C1-C6 alcohol with a C2-C6 carboxylic acid. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što je organsko otapalo odabrano iz skupine koja se sastoji od Ci-Ci9 alkohola, estera C;-C19 alkohola s Ci-Cio karboksilnim kiselinama 1 njihovih smjesa, a poželjno se sastoji od C;-C$ alkohola i estera C,-Cg alkohola s C2-Cg karboksilnom kiselinom.
A compound of the formula wherein X is selected from the group consisting of H, F, Cl, Br, and I; wherein Y1, Y2, Y3, Y4, and Y5 are independently selected from the group consisting of S, S-O-, S=O, O--S=O, and O=S=O; and wherein R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, alkyl, and aryl. 
2) naznačen time, da se X odabire iz skupine koja se sastoji od H, F, Cl, Bril; u čemu su Yi, Y2,Y3,Y41 Ys nezavisno odabrani iz skupine koja se sastoji od, S, S-O', S=0, O'-S=0 i O=S=0; iu čemu se Ri, R2, Ra, Ra, Rs, Rs, Rz i Rg, nezavisno odabiru iz skupine koja se sastoji od H, OH, alkila i arila, uz uvjet da je barem jedan od Y;, Y2,Y3,Y41 Ys različit od S.
In an embodiment the predetermined inner rim joint angle (a) is −20 to 20°, in particular −10 to 10°, in particular −5 to 5°, in particular −2 to 2°. In an embodiment the alignment frame (62) is “C”-shaped. 
Preša (1) prema prethodnom patentnom zahtjevu pri čemu prethodno određeni spojni kut (0) unutrašnjeg ruba je 20 do 20", naročito -10 do 10%, naročito -5 do 5%, naročito -2 do 2".
The nucleic acid of claim 6, wherein the non-human regulatory element is a rodent regulatory element, such as a mouse regulatory element. 
Nukleinska kiselina prema zahtjevu 6, naznačena time, da ne-ljudski regulacijski element je glodarski regulacijski element kao što je primjerice mišji regulacijski element.
forming rifaximin granules by dry granulating a mixture of the rifaximin and the one or more of an in-tragranular excipient; 
- < oblikovanje granula rifaksimina pomoću suhe granulacije smjese rifaksimina i jednog ili više intragranularnih ekscipijenata;
Further aspects of the invention are described in the following clauses: A composition comprising a protein having a free thiol and a carbohydrate, wherein the carbohydrate is present in an amount sufficient to maintain the stability of the protein and wherein the pH of the composition is less than 7.0. 
Farmaceutska kompozicija koja sadrži protein koji ima slobodni tiol i ugljikohidrat, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za održavanje stabilnosti proteina i pri čemu je pH kompozicije između 4,5 1 6,5, pri čemu je protein koji ima slobodni tiol glukocerebrozidaza (GCB) i pri čemu je ugljikohidrat saharoza.
In vitro example 3. 
Zn vitro primjer 3.
If the anti-inflammatory agent is administered at the same time as the pharmacologic agent, the two can be administered as a combined formulation or separately. 
Farmakološko sredstvo za uporabu prema zahtjevu 1, naznačeno time da se inhibitor degranulacije mastocita ili antihistaminik daje istovremeno kao i farmakološko sredstvo.
Y' is selected from -H, an oxo group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms; 
Y' se izabire između -H, okso skupine, vezne skupine s vezanom reaktivnom skupinom na sebi, po izboru supstituirani linearni, razgranati ili ciklički alkil, alkenil ili alkinil s 1 do 10 atoma ugljika, po izboru supstituirani 6- do 18-eročlani aril, po izboru supstituirani 5- do 18-eročlani heteroarilni prsten s jednim ili više heteroatoma koji su nezavisno izabrani između dušika, kisika i sumpora, po izboru supstituirani 3- do 18-eročlani heterociklički prsten s 1 do 6 heteroatoma;
converting said series of blocks into a character string based on a conversion table, 
(c) pretvaranje spomenutog spoja čvorova u povezani niz znakova temeljem tablice konverzije,
Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose. 
Primjeri krutih nositelja su laktoza, terra alba, sukroza, ciklodekstrin, talk, želatina, agar, pektin, akacija, magnezijev stearat, stearinska kiselina i niži alkilni eteri celuloze.
electrically driving the active load (50) so as to continue absorbing energy from the candidate signal (Sc) during at least a time (TV) required for performing the validation. 
- električnom pogonjenju aktivnog tereta (50) kako bi nastavio apsorbirati energiju iz kandidatnog signala (S.) u najmanju ruku u vremenu (Ty) potrebnom za provođenje provjere.
An underlayment adapted to receive and secure at least one heating element of a radiant heating assembly, comprising: 
Podloga (1), prilagođena za primanje i osiguravanje najmanje jednog grijaćeg elementa sklopa za grijanje zračenjem, koja sadrži:
wherein a unique identifier for a MPEG-2 transport stream packet comprises or is derived from a presentation time stamp, an additional counter, and a continuity counter. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se određuje jedinstveni identifikator za prijenos paketa struje MPEG-2 koji se sastoji od ili se dobiva iz prezentacijskog vremenskog biljega, dodatnog brojača i brojača kontinuiteta.
The reaction can be performed in the presence of a base or a cyanide salt. 
Reakcija može biti provedena u prisutnosti baze ili cijanidne soli.
the deletion of the serine at position 129, 130, and 139, and the replacement of the threonine at 133 and serine at position 136 with an alanine, or 
brisanje serina na položaju 129, 130, i 139, i zamjenu treonina na 133 i serina na položaju 136 sa alaninom, ili
reacting the compound of the Formula V with a suitable sulphonylating agent in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula IIa. 
(e) reakciju spoja formule V sa tosilkloridom in situ sa svrhom dobivanja sulfonatnog estera u prisutnosti prikladne baze i toluena sa svrhom dobivanja spoja sa formulom JI.
Four smoking articles were constructed as shown in Figure 2 with a 10 mm pressed carbon fuel element having the tapered lighting end illustrated in Figure 2A. 
A. Četiri proizvoda za pušenje konstruirana su kao što je prikazano na slici 2 sa ugljičnim gorivim elementom od 10 mm prešanog ugljika koji ima zarubljeni kraj za paljenje kao što je ilustrirano na SI. 2A.
A composition for use according to any one of the preceding claims wherein the composition is in the form of a surfactant system, water-in-oil emulsion, oil-in-water emulsion, serum, gel, oil, aqueous solution, hydroalcoholic solution, anhydrous sticks, compact founding powder, lotion, milk, suncream, after sun product or camouflage product. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak u obliku surfaktantnog sustava, emulzije vode u ulju, emulzije ulja u vodi, seruma, gela, ulja, vodene otopine, hidroalkoholne otopine, bezvodnih štapića, kompaktnog temeljnog pudera, losiona, mlijeka, kreme za sunčanje, proizvoda nakon sunčanja ili proizvoda za korekturu.
A compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R6 is C2-3 alkyl substituted by hydroxy. 
Spoj u skladu s patentnim zahtjevom 7 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R* je Cx.; alkil supstituiran s hidroksi.
An assembly (1) according to claim 1-2, wherein the connection means are arranged for coaxial alignment of the opening (19) of the lid (5) with the second end of the dispensing line channel (7). 
Postupak prema zahtjevu 2 ili 3, naznačen time, da su sredstva za spajanje (9 i 17) raspoređena za koaksijalno postavljen otvor (19) poklopca (5) sa drugim krajem priključnog kanala za točenje (7). tr>
wherein a quantity of the at least one removably insertable high frequency AC to DC power converter modules included in the modular AC to DC converter unit is adjustable in order to achieve a desired output power. 
Ugradivi punjač za električna vozila (201) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se broj visokofrekventnih modula za pretvaranje struje uključenih u modularnu jedinicu za pretvaranje izmjenične struje u istosmjernu može podesiti kako bi se postiglo željenu izlaznu snagu.
The use according to claim 7, wherein the compound according to claim 3 or the pharmaceutical composition according to claim 5 is administered in patches, ointments, creams, suspensions, lotions, pastes, gels, sprays, foams or oils. 
Uporaba u skladu s patentnim zahtjevom 7, naznačena time, da se spoj u skladu s patentnim zahtjevom 3 ili farmaceutski pripravak u skladu s patentnim zahtjevom 5 primjenjuje u flasterima, mastima, kremama, suspenzijama, losionima, pastama, gelovima, sprejevima, pjenama ili uljima.
A further subgroup of compounds according to the invention is represented by compounds of formula (Ic): 
Daljnju podskupinu spojeva prema ovom izumu predstavljaju spojevi formule (Ic): (R')
5-(4-(cyclopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof. 
-(4-(ciklopropilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; kao i njihove farmaceutski prihvatljive soli, kompleksi, hidrati, solvati ili polimorfi, tautomeri, geometrijski izomeri, optički aktivni oblici i farmaceutski aktivni derivati.
These experiments were conducted using fresh washed human platelets stimulated with 2 µM ADP and spiked with either Rapamycin or 42-O-(D-Fructosylcarbonyl)rapamycin at time zero. 
Ovi pokusi provedeni su na svježe ispranim ljudskim trombocitima stimuliranima s 2 uM ADP i potaknutima rapamicinom ili 42-O-(D-fruktozilkarbonil)rapamicinom u vremenu nula.
A pharmaceutical composition for use in the treatment of an inflammatory disease caused by the expression of cytokine subunit p40 by systemic or topical administration, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, psoriatic arthritis, and psoriasis wherein said pharmaceutical composition comprises benzydamine or the physiologically acceptable acid addition salts thereof. 
Farmaceutski sastav, naznačen time, da se upotrebljava u liječenju upalne bolesti uzrokovane ekspresijom podjedinice p40 citokina, pomoću sustavne 1li topikalne primjene, pri čemu je navedena upalna bolest odabrana iz skupine koju čine Chronova bolest, psorijatski artritis i psorijaza, dok navedeni farmaceutski sastav obuhvaća benzidamin ili njegove fiziološki prihvatljive kiselinske adicijske soli.
a monoclonal antibody comprising a light chain variable domain containing residues 44-54, 70-76 and 109-117 of SEQ ID NO:2; 
(i) monoklonalnog antitijela koje sadrži varijabilno područje lakog lanca koje sadrži ostatke 44-54, 70-76 i 109-1170d SEQ ID br. 2;
The resulting slurry was cooled to 2 °C, aged for 30 min and filtered. 
Rezultirajuća smjesa je ohlađena na 2"C, ostavljena 30 min i filtrirana.
In addition, stabilizers may be added.. 
Uz to, može se dodati i stabilizatore.
The organic phase was washed with brine, dried with MgSO4 and concentrated in vacuo to give 10.0 g 2-allylsulfanyl-benzamide (51.7 mmol, 94%). 
Organska faza oprana je rasolom osušena s MgSox i koncentrirana in vacuo kako bi se dobilo 10.0 g 2-alilsulfanil-benzamid (51.7 mmol, 94%).
In one embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 5; a heavy chain variable region CDR2 of SEQ ID NO: 19; a heavy chain variable region CDR3 of SEQ ID NO: 33; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 61; and a light chain variable region CDR3 of SEQ ID NO: 75. 
(e) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 5; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 19; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 33; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 47; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 61; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 75;
None of the cited prior art provides a practical, compact, hand-held wireless remote control device that allows essentially full control over the operation of a yacht or other marine vessel. 
Nijedna od prethodno navedenih izvedbi ne omogućuje praktični, kompaktni, ručni bežični daljinski upravljački uređaj koji omogućuje osnovnu punu kontrolu nad kretanjem jahte ili drugom pomorskog plovila.
Stirred at 50 °C over night, then the solvent was removed under reduced pressure. 
Miješa se na 50 "C preko noći, potom se otapalo ukloni pri sniženom tlaku.
In some embodiments, the condition is a skin disease or disorder such as dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, disorders of skin pigmentation, an aging-related skin condition; a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, skin cancer, or a disorder involving hyperproliferation of skin cells. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je kožna bolest ili poremećaj koji se bira od dermatitisa, toplinskih ili kemijskih opeklina, kronične rane, akni, alopecije, drugih poremećaja folikula kose, bulozne epidermolize, opeklina od sunca, komplikacija opeklina od sunca, poremećaja pigmentacije kože, stanja kože povezanog sa starenjem, rana nakon operacije, ožiljka od ozljede kože HR P20171275 T1 ili opeklina, psorijaze, dermatološke manifestacija autoimune bolesti ili bolesti presatka protiv domaćina, raka kože, te poremećaja koji obuhvaćaju hiperproliferaciju stanica kože.
The pharmaceutical composition of any one of claims 2 to 7, wherein the pharmaceutical composition has a pH of about 4. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 1-3, koja dodatno sadrži agens za stabilizaciju.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for the use according to claim 22, wherein the disease is acute lymphoblastic leukemia. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 17, naznačeno time da je bolest akutna limfoblastična leukemija.
A compound of the formula (I) or a salt thereof: in the formula, 
Spoj sa formulom (I) ili njegova sol: u formuli,
Process according to anyone of the preceding claims, wherein it is provided a step of preparing reinforcing fibres to be arranged inside the mould, said preparing step comprising: arranging in a plane a plurality of layers of said reinforcing fibers, optionally wherein each of said layers exhibits a respective width and a respective length different from the ones of the other layers, 
– postavljanju u ravnini više slojeva navedenih ojačavajućih vlakana, izborno gdje svaki od navedenih slojeva ima odgovarajuću širinu i odgovarajuću duljinu različite od onih kod drugih slojeva, – u najmanju ruku djelomičnom preklapanju sa svim drugim navedenim slojevima, – namatanju navedenih slojeva na namatač, izborno na cjevasti namatač.
A combination according to any one of the preceding claims characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno bilo kojem prethodnom patentnom zahtjevu, naznačena time, da djelatni sastojci (a) i <b) čine jedinstveni farmaceutski pripravak.
In one embodiment, R1 is selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted aryl, 
Spoj prema Zahtjevu 1, naznačen time, da R, je odabran iz skupine koja sadrži (1) supstituirani i nesupstituirani alkil,
This results in the desired distribution of droplet sizes. 
To ima za posljedicu željenu razdiobu veličine kapljica.
9.2 g Z-Phg-OH are added to the grey suspension at RT. 
U sivu suspenziju se doda 9,2 g Z-Phg-OH na RT.
Strength of the mixture of polypeptides of the invention 
Datum objave europske prijave patenta: